Industrial & Medical Gases Nigeria Plc reported a revenue earlier than tax of N1.42 billion for the yr ended December 2025, in line with its unaudited {financial} statements.
Though the corporate remained worthwhile, this represents a decline from the N2.44 billion recorded within the prior yr, as greater working bills weighed on bottom-line efficiency.
Within the fourth quarter of 2025, pre-tax revenue rose to N204.9 million, up from N160.2 million within the corresponding interval of 2024, reflecting improved quarterly earnings.
Nonetheless, fourth-quarter income softened, falling to N1.7 billion from N2.1 billion a yr earlier, whereas full-year income remained agency at N8.3 billion.
Income for the yr inched as much as N8.37 billion, pushed largely by fuel gross sales, which continued to dominate the enterprise, accounting for 96.5% of complete turnover.
On the price facet, the value of gross sales narrowed to N4.2 billion from N4.4 billion within the prior yr, supporting an enchancment in gross revenue, which rose 4.72% to N4.07 billion.
The corporate additionally recorded different revenue of N115.9 million, primarily from generator rent and positive factors on scrap gross sales.
Nonetheless, this was overshadowed by rising working bills.
In consequence, working revenue declined sharply to N1.3 billion from N2.4 billion within the earlier yr.
After factoring in finance revenue of N48.1 million and no finance prices, revenue earlier than tax settled at N1.42 billion, down from N2.44 billion in 2024.
In a constructive growth, complete liabilities fell sharply to N2.9 billion from N8.9 billion a yr earlier.
Shareholders’ fairness strengthened considerably, rising to N11.7 billion from N5.9 billion within the prior yr, with normal reserves making up 96.9% of complete fairness.
Primarily based on the buying and selling data supplied, Industrial & Medical Gases Nigeria Plc shares are at present priced at N34.65, up 10% month-to-date in February 2026.
The inventory seems to be rebounding from a January low of N31.50 and has since traded above the N34 stage in February, seemingly supported by improved investor sentiment following the discharge of its {financial} outcomes.
